secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0001641172-25-012617
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 3.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology closes $695K private placement of stock and warrants for THIO-101 trial
--------------------------------------------------------------------------------

- Sold 463,332 shares and warrants at $1.50/share; warrants exercisable at $1.71, 5-year term, 6-month lockout.
- Director Stan Smith purchased 33,333 shares and warrants for ~$50,000.
- Gross proceeds ~$695,000; net proceeds to fund Step 1 of Part C of Phase II THIO-101 trial and working capital.
- Expected closing May 29, 2025; securities exempt from registration under Section 4(a)(2)/Rule 506.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225012617/0001641172-25-012617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225012617/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-012617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer